AtriCure, Inc. (ATRC) Stock
ATRC has an Alpha Score of 47 out of 100 (weak), computed on Nov 5, 2026 from 3 of 4 sub-scores. 2 members of Congress disclosed 9 trades in ATRC since 2019: 6 purchases and 3 sales, most recently Gilbert Cisneros (partial sale, Sep 29, 2026). 6 of the hedge funds AlphaScala tracks reported ATRC in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $37.32M. Company insiders reported 0 open-market buys and 6 sales on SEC Form 4 in the 90 days to Nov 5, 2026. Its trailing P/E ratio is 298.6 and its net margin 1.8% (key statistics as of Oct 29, 2026).
What is ATRC's Alpha Score?
How it works →Alpha Score of 47 reflects weak overall profile with strong momentum, poor value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 5, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded AtriCure, Inc. (ATRC)?
Most recent: Gilbert Cisneros (partial sale, Sep 29, 2026); records start Jun 27, 2019.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-09-29 | partial sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-08-20 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-03-03 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-05-06 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2024-07-19 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2024-06-18 | sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2021-06-08 | partial sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2020-03-31 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all ATRC political trades →Which hedge funds own ATRC?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 1.33M | $37.32M | -9% |
| Point72 Steve Cohen | 604K | $16.91M | NEW |
| Renaissance Technologies Jim Simons (founder) | 234K | $6.55M | -24% |
| D.E. Shaw David Shaw | 193K | $5.40M | +241% |
| Citadel Ken Griffin | 177K | $4.96M | +103% |
| Bridgewater Associates Ray Dalio | 76K | $2.14M | +128% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are AtriCure, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 4, 26 | Privitera Salvatore | Chief Technical Officer | SELL | 8.4K | $546K |
| Sep 23, 26 | Privitera Salvatore | Chief Technical Officer | SELL | 4.5K | $271K |
| Sep 11, 26 | Groves Regina E | Director | SELL | 5.3K | $288K |
| Sep 8, 26 | Privitera Salvatore | Chief Technical Officer | SELL | 3.7K | $201K |
| Sep 2, 26 | Privitera Salvatore | Chief Technical Officer | SELL | 7.8K | $408K |
| Aug 24, 26 | Dahlquist Karl S. | Chief Legal Officer | SELL | 9.4K | $458K |
| Aug 5, 26 | Prange Karen | Director | SELL | 3.6K | $138K |
| Aug 5, 26 | Yuen Maggie | Director | SELL | 3.5K | $134K |
| Jul 29, 26 | Noznesky Justin J | Chief Mktg & Strategy Officer | SELL | 6.2K | $240K |
| Jul 28, 26 | Wehrwein Sven | Director | SELL | 25.0K | $946K |
SEC Form 4 filings as of Nov 5, 2026
See cluster-buy signals across all tickers →What are ATRC's key statistics?
Key statistics as of Oct 29, 2026
How does ATRC's valuation compare with the Healthcare sector?
| Metric | ATRC | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 298.6 | 28.7 | 108 |
| Net margin | 1.85% | 4.11% | 160 |
| Return on equity | 2.14% | 5.18% | 180 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 6, 2026). P/E excludes loss-making companies.
ATRC price chart
Powered by TradingViewWhat does AtriCure, Inc. do?
AtriCure, Inc. is a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. The company develops and provides advanced medical technologies used by electrophysiologists, cardiothoracic surgeons, and thoracic surgeons worldwide to address complex Afib cases and related conditions. Key products include the Isolator Synergy Ablation System, the first medical device approved by the FDA for treating persistent Afib, featuring single-use disposable radiofrequency clamps, multifunctional pens, and linear ablation devices for open and minimally invasive procedures. The AtriClip Left Atrial Appendage Exclusion System offers solutions for LAA management during surgical interventions. Additionally, the Hybrid AF Therapy provides a minimally invasive option for long-standing persistent Afib patients, while the cryoICE cryoSPHERE probes enable temporary ablation of peripheral nerves to alleviate pain in cardiac and thoracic surgeries. AtriCure's EPi-Sense Guided Coagulation System with VisiTrax Technology supports minimally invasive ablation. Headquartered near Cincinnati, Ohio, the company focuses on delivering best-in-class solutions that enhance patient outcomes in cardiothoracic procedures.